Ashley Shoemaker, MD, MSci, discusses the evolving clinical pathways for managing rare genetic and acquired hypothalamic obesity in pediatric patients.
Ashley Shoemaker, MD, MSci
Advertisement
Ashley Shoemaker, MD, MSci, is an associate professor of pediatrics and pediatric endocrinology at Vanderbilt Health.
Articles by Ashley Shoemaker, MD, MSci
The FDA approval of setmelanotide for patients 4 years and older offers a targeted therapy to address the underlying biology of acquired hypothalamic obesity.
A first-of-its-kind approval for hypothalamic obesity offers earlier, targeted treatment in children.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Julie Khlevner, MD, discusses the impact of FDA-approved LINZESS for functional constipation
2
FDA approves ensitrelvir for post-exposure prevention of COVID-19 in adolescents and adults
3
Recognizing the skin findings that distinguish pediatric hidradenitis suppurativa
4
Colleen Cotton, MD, on the importance of early recognition in hidradenitis suppurativa
5